A fluorescent micrograph of a section of brain affected by Parkinson's disease. Neuron nuclei are blue, while the protein ...

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says the ...

Across two cohorts, the Automated Imaging Differentiation for Parkinsonism (AIDP) machine learning model distinguished ...

This article originally appeared in Research Colorado.Research at the University of Denver is showing promise for the ...

Northwestern Medicine investigators have uncovered new insights into how metabolic dysfunction contributes to Parkinson's ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment ...

Lewy body dementia (LBD) and Parkinson’s disease dementia share a common cause: abnormal deposits of a protein called alpha-synuclein that form in the brain. These deposits, known as Lewy bodies ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies ...

The findings reveal that TFE3 activation facilitates the clearance of toxic alpha-synuclein aggregates and restores mitochondrial function, two crucial aspects of PD progression. As a leading ...

The nanobodies the researchers developed can target different assemblies of amyloid-beta and alpha-synuclein, proteins associated with Alzheimer's and Parkinson's diseases, respectively.